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and model 1 + initiating-service groups (model 3). Optimism-corrected C-statistics 
and root mean square error (RMSE) were used to compare model prediction accu-
racy. Results: The cohort consisted of 3,105 individuals; of which 38.3% had a 
recurrent episode, with an average cost of $3,803CAD (SD= $11,959). LCA identified 
two groups: high user (15.2%) and low user (84.8%), while about 51.6% of the cohort 
was grouped as institutionalized. Model 2 predicted time to a subsequent episode 
better (C-statistic = 0.94) than model 3 (C-statistic = 0.91), and model 1 (C-statistic 
= 0.87). Model 3 predicted cost of the subsequent episode better (RMSE= 11934.5) 
than model 2 (RMSE= 11999.8) and model 1 (RMSE= 12075.3). ConClusions: The 
findings suggest that both LCA-defined groups and initiating-service groups could 
be used to summarize past utilization for risk prediction modeling; the choice may 
depend on the outcome of interest.
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objeCtives: Hospital efficiency is the focus of several studies and increasingly, 
data envelopment analysis (DEA) is used to compute and compare efficiencies of 
hospitals for quality improvement and policy analysis. DEA is a non-parametric 
approach to compute efficiency considering multiple inputs and outputs and bench-
mark hospitals, with the presumption that the inefficient hospitals can reduce 
inputs and/or increase outputs to improve their efficiency. Hospitals are complex 
systems and have multiple non-discretionary inputs, such as type of hospital or 
region of location that are not under the control of administration, and hence cannot 
be altered. This study emphasizes the need to consider non-discretionary inputs 
in DEA models. Methods: One year’s worth of Agency for Healthcare Research & 
Quality’s Health Care Utilization Project data was used. Variables included full-time 
equivalent of registered nurses, licensed practical nurses and nurse aides as inputs 
and total discharges and percent of surgeries as outputs, with bed size, urban/
rural, teaching status, region and ownership as non-discretionary inputs. First a 
variable-returns-to-scale DEA model was run without the non-discretionary inputs. 
Next the model was repeated including an environmental harshness (created using 
regression). Results: When the efficiency scores of the 862 hospitals in the two 
stages were compared, 755 hospitals had increased efficiency, and mean increased 
more than three times from 0.11 (P< 0.000) and standard deviation doubled from 
0.15. The number of efficient hospitals increased from 12 to 72. ConClusions: 
DEA can be a sophisticated method to measure hospital efficiency. Not accounting 
for non-discretionary inputs can radically alter the efficiency scores and bias study 
results. The first stage score has inefficiency and the effect of non-discretionary 
inputs. Since both mean and standard deviation increased dramatically, simple nor-
malization cannot be used as a proxy. Appropriate treatment of non-discretionary 
inputs is necessary to make meaningful comparisons to inform quality and policy 
interventions.
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objeCtives: Previous studies have investigated changes in risk factor (RF) variables 
on cost and outcomes in the IMS-CORE-Diabetes-Model (CDM) using UKPDS-68 
(UK-68-RE) and UKPDS-82 risk equations (UK-82-RE). The objective of this study 
was to project health benefits and total lifetime costs (TLC) associated with a range 
of selected RF changes utilizing UK-68-RE versus recently implemented RE within 
the CDM: the Swedish-National-Diabetes-Registry (S-NDR) and the ADVANCE-
Risk-Engine (ARE). Methods: The CDM was applied to project the lifetime ben-
efits (life years (LYs), quality adjusted life years (QALYs)) and TLC ($US) associated 
with baseline RF changes for HbA1c (+/-1%), body-mass-index (BMI) (+/-1 Kg/m2), 
systolic-blood-pressure (SBP) (+/-20 mmHg), total-cholesterol (TC) (+/-10 mg/dl), 
(high-density-lipoprotein (HDL) (+/-5 mg/dl) and low-density-lipoprotein (LDL) (+/-
10 mg/dl). An intermediate risk type-2 diabetes cohort (age 52 years, HbA1c 8%, SBP 
140 mm-Hg, BMI 30 Kg/m2, HDL 50 mg/dl and LDL 150 mg/dl) was projected over 
lifetime to explore the sensitivity of discounted (3%) LYs, QALYs and TLC per unit RF 
variation. Results: When UK-68-RE were applied, projected changes in LYs were: 
0.096, 0.045, 0.013, 0.071, -0.183 and 0.0 and QALYS: 0.156, 0.067, 0.065, 0.051, -0.121 
and 0.0 for RF variations in HbA1c, SBP, BMI, TC, HDL and LDL, respectively. This 
compared to changes of 0.103, 0.032, 0.004, 0.070, -0.195, 0.044 (LYs) and 0.150, 0.049, 
0.054, 0.050, -0.132, 0.025 (QALYs) utilizing S-NDR-RE and 0.103, 0.030, 0.001, 0.065, 
-0.093, 0.0 (LYs) and 0.163, 0.057, 0.056, 0.048, -0.062, 0.0 (QALYs) utilizing ARE-RE. 
TLC decreased by $3’479, $1’065, $69, -$414, $1’263, $0, (UK-68-RE); $2’829, $852, $81, 
-$289, $910, -$347 (S-NDR-RE ) and $3’488, $1’196, -$10, -$182, $694, $0 (ARE-RE) for 
RF variations in HbA1c, SBP, BMI, TC, HDL and LDL, respectively. ConClusions: 
The degree to which RF changes are translated into benefits and costs may change 
considerably dependent on the choice of selected risk equations.
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objeCtives: To investigate the costs associated with the management of patients 
who sought emergency care due to DRMs. Methods: This study was a retrospec-
tive analysis of patients’ medical records. 535 patients sought emergency services 
over a six-month period in a large teaching hospital in Brazil and those with DRM 
situation 3; CIs cannot defined), the combination of the two proposed methods 
produces CIs as single range. ConClusions: We reviewed the issues related to 
using the conventional methods to calculate ICER CIs, and proposed new methods 
to address these. Proposed methods yield CIs that can be more easily interpreted. 
However, some issues remain that require further discussion.
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objeCtives: To describe the methodology used to identify treatment cycles and 
determine real-world outcomes associated with the in vitro fertilization (IVF) treat-
ments, follicle-stimulating hormone (FSH) versus FSH+human menopausal gonado-
tropin (hMG), using administrative claims data. Methods: This retrospective study 
used the Truven Healthcare MarketScan® Claims Database to identify and compare 
IVF treatment protocols, pregnancy and birth outcomes among women aged 18–< 35 
undergoing IVF between January 2009 and December 2012. Patients with ≥ 1 claim for 
a gonadotropin-releasing hormone agonist (GnRHAg) or antagonist (GnRHAnt) (first 
claim being the index date), ≥ 1 claim for FSH and ≥ 1 claim for human chorionic gon-
adotropin (hCG), using National Drug Codes, were selected. Patients were included 
on identification of a prescription for FSH in the 7 days pre-index through 60 days 
post-index, hCG in the 60 days post-index and ≥ 1 embryo transfer (ET) code (using 
current procedural terminology) ≤ 60 days post-index. The FSH+hMG cohort also 
required identification of ≥ 1 claim for hMG ≤ 60 days post-index. Patient eligibility 
was defined as continuous enrollment for 12 months prior and 18 months post-
index. ICD-9-CM codes were used to identify live birth outcomes within 42 weeks 
of ET. Results: Inclusion/exclusion criteria identified 627 and 852 patients in the 
FSH and FSH+hMG cohorts, respectively. The 18-month post-index eligibility criteria 
accounted for a large number of patients removed (n= 7366). No differences in first-
cycle outcomes were seen between FSH and FSH+hMG for: live birth per ET (38.1% 
vs 38.5%; OR 1.02 [95%CI: 0.82–1.26], p= 0.871) and live birth per pregnancy (54.44% 
vs 54.37%; OR 1.00 [95%CI: 0.78–1.28], p= 0.98), respectively. ConClusions: Most 
published analyses of fertility treatment outcomes are derived from single fertility 
center datasets. This methodology successfully identified two distinct IVF treatment 
protocols and allowed comparison of outcomes using real-world healthcare claims 
data sourced from a variety of fertility centers.
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objeCtives: Kidney disease is a common condition in which kidneys fail to func-
tion properly. In this study, the highest incidence and prevalence rates of end-
stage renal disease [ESRD] (i.e.,both renal transplant and dialysis) were reported 
from the USA, Taiwan, and Japan. In the Arab countries of the Middle East, Saudi 
Arabia recorded the highest prevalence of patients with renal failure of 600 cases 
per million of population, while Kuwait recorded the lowest prevalence rate of 
80 cases per million. In the West Bank, the total number of renal failure patients 
was 692 in the first quarter of 2012—an increase of 11.3% over the same period in 
2011. Methods: Prospective estimates and elicited expert opinions are used to esti-
mate the unit costs of hemodialysis and / or kidney transplantation in the Palestine. 
Our study retrospectively reviewed epidemiological data on hemodialysis including: 
1. Number of patients receiving hemodialysis; 2. Incidence rate; 3. Total mortality. 
The direct cost of kidney transplantation was estimated by dividing the procedures 
into three phases: (1) pre-transplant, (2) transplant, and (3) post-transplant. Cost 
analysis for hemodialysis was performed for each patient on dialysis. Results: 
The average cost for kidney transplant was US$16,277 for the first year; the esti-
mated cost of a single hemodialysis session was US$97; while the cost of hemo-
dialysis per patient was variable, it averaged $16,085 per year—nearly as much 
as a transplant. ConClusions: While live, related kidney donors are scarce, our 
study revealed that kidney transplant was more adequate and less expensive than 
hemodialysis. These results were similar to many related studies, and have direct 
resource allocation implications for government-funded kidney disease services 
funded by through Palestinian Ministry of Health.
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objeCtives: The study objective was to compare the incremental predictive value 
of a probability-based classification versus a deterministic grouping of previous 
healthcare use for subsequent healthcare outcomes. Methods: Administrative 
databases from Saskatchewan, Canada (population 1.1 million) were used to identify 
an incident chronic obstructive pulmonary disease (COPD) cohort (35+ years). All 
episodes of healthcare use for COPD exacerbations between 2007/08 and 2011/2012 
fiscal years were identified. Latent class analysis (LCA) probabilistically grouped the 
cohort based on healthcare utilization in the index episode using visits to general 
practitioners (GP), specialists, emergency departments (ED), inpatient hospitaliza-
tions (IH), and outpatient medication dispensations. Individuals were also deter-
ministically grouped as institutionalized (IH/ED) or ambulatory (GP/specialist) based 
on the initiating service of the index episode. Time to a subsequent episode and 
the cost of the subsequent episode were modelled with Cox proportional hazard 
regression and generalized linear models, respectively; using only demographic 
and disease characteristics (model 1), model 1 + LCA-defined groups (model 2), 
